Cabinet Medical Individual Lauderma
- Address
- lock Available on a paid plan
Cabinet Medical Individual Lauderma - Dermatological Immunology Research
Cabinet Medical Individual Lauderma is a specialized medical research facility focused on advancing treatments for complex autoimmune skin conditions. The center demonstrates particular expertise in investigating novel therapeutic approaches for challenging dermatological manifestations of systemic autoimmune diseases.
- Cutaneous lupus erythematosus treatment development
- Biologic therapies for autoimmune skin disorders
- Phase III clinical trial coordination and patient care
The center's research focuses on evaluating anifrolumab, a targeted biologic therapy, for patients with chronic and subacute cutaneous lupus erythematosus (CLE). Their participation in multi-stage efficacy and safety studies demonstrates commitment to establishing superior treatment options that can meaningfully improve skin manifestations in patients suffering from these debilitating autoimmune conditions.
Site Overview
Activity Indicator
Last 6 months
Trial Flow
How this site's trials are distributed across therapeutic areas and active substances (IMPs), and how they're positioned within their overall lifecycle status. Flow thickness represents the number of unique trials.
Compounds & Molecules Timeline
The time span of clinical-trial activity for the main active substances (IMPs) studied at this site over the last 8 years. Each bar runs from the earliest trial start to the most recent end; a substance with a trial still open has no recorded end and is shown as ongoing.
Sponsor & Partnership
Top sponsors by active trials, and the ones that have come back for more than one study.
Sponsor Network
Top 1 by active trials.
Partnership History
Sponsors with repeated collaboration (≥ 2 trials).
- 1Alumis Inc.2trials
Sponsor Network Graph
How sponsors and therapeutic areas connect across this site's active trials: each link is at least one active trial shared between them, and bigger nodes mean more activity. Click a node to see its exact connections.
Country Benchmark
Compared to 442 other sites in Romania
Therapeutic Area Benchmark — Romania
Select a therapeutic area to compare against other sites in Romania.
Competitor Comparison
Similar sites in the same country running a comparable number of trials (within ±30%), scored on how closely their trial portfolios match this one. Higher percentages mean a more similar profile.
Country: Romania
Market Share
Country: Romania
Therapeutic Area Market Share
Select a therapeutic area to view its disease coverage breakdown.
Heat Maps & Advanced Analytics
How often specific conditions appear in trials across this site and comparable sites from the same country. Each row is a site, each column a condition, and each cell the number of trials on it — darker means more activity.
Other Trials in Cabinet Medical Individual Lauderma
lock Showing 1 of 4 trials — the rest is available on a paid plan.
| Trial | Sponsor | Phase | Status | Start Date | End Date |
|---|---|---|---|---|---|
| A Phase 3b/4 Multi-center, Randomized, Open-label, Long-term Safety Study of Deucravacitinib in Comparison to Ustekinumab in Participants with Moderate-to-Severe Plaque Psoriasis (PRAGMATYK) | Bristol-Myers Squibb Services Unlimited Company | Phase I | Recruiting | May 2026 | — |
IMP list
lock Showing 1 of 5 compounds — the rest is available on a paid plan.
| IMP | Trials | Status | First start | Last start |
|---|---|---|---|---|
| Envudeucitinib | 2 | Unknown | 2025-02-20 | 2025-06-13 |
Upgrade this site to Business Plan
Own the profile, publish your feasibility data and reach sponsors directly.
Is something out of date?
Tell us what needs correcting and we'll update this profile.
lock Available to Business plan sites only.